Speedy US approval for Amgen’s Lumakras was an embarrassment for Mirati, which has gone quiet as its share price has drifted downwards.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,